Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Study Suggests GAMMAGARD LIQUID May Target the Primary Pathway Involved in Alzheimer's Disease
May 2nd, 2008
The University of Tennessee Health Science Center and Baxter International Inc. (NYSE:BAX) announced data from a laboratory study demonstrating natural antibodies contained in GAMMAGARD LIQUID [Immune Globulin Intravenous (Human)] (IGIV), marketed as KIOVIG in the European Union, a plasma-derived antibody replacement therapy indicated for primary immunodeficiency disorders and being studied in Alzheimer's disease, binds directly to multiple aggregated, or clustered, forms of the beta-amyloid peptide molecule. The beta-amyloid molecule may contribute to beta-amyloid plaques, which are thought to be the primary culprit causing Alzheimer's disease. The results of this in vitro (laboratory)...
Source: Health Business Week (2008-05-02)
|
